HomeDilutionPromotionUplist RadarBuzzToday on EDGARDead Stock Check
PubCo Insight › Tickers › NTLA

$NTLANASDAQ NMS - GLOBAL MARKET

Intellia Therapeutics, Inc.
Biotechnology
Market Cap
$1.58B
Exchange
NASDAQ NMS - GLOBAL MARKET
Filings (365d)
24
News (14d)
4
CIK
0001652130
Website
Company site ↗
SEC Filing Timeline
8-KSep 08, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KSep 04, 2026
Material agreement · Items 1.01,2.03,7.01,9.01
10-QAug 06, 2026
Quarterly report
8-KAug 06, 2026
Earnings release · Items 2.02,9.01
8-KJun 15, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJun 10, 2026
Shareholder vote results · Items 5.07
10-QMay 11, 2026
Quarterly report
8-KMay 11, 2026
Earnings release · Items 2.02,9.01
Recent News (Finnhub)
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Yahoo · Oct 21
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Yahoo · Oct 20
Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance
Yahoo · Oct 18
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
Yahoo · Oct 13
Source-linked from SEC EDGAR + Finnhub aggregated news.
Not investment advice. Always verify on SEC.gov directly.
Investor relations · NTLA
Is this how AI describes Intellia Therapeutics, Inc.?
This page is the public, source-linked snapshot that investors, brokers, and AI assistants pull for NTLA: EDGAR filings and recent news, no editor, no spin. When an AI engine or a financial terminal shows stale, misclassified, or missing data for your ticker, that is the first thing investors see. Pulse IR runs a free 24-hour audit of how ChatGPT, Perplexity, Google, and the major terminals currently represent NTLA, and can correct it.
Get the free AI visibility audit
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
PubCo Insight

See the dilution and promotion flags before you see the pitch.

Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.

Every flag links to its EDGAR filing so you can check it yourself. Sponsored coverage disclosed under SEC 17(b). One-click unsubscribe.